Abstract
Positron emission tomography (PET) is a powerful and rapidly developing area of molecular imaging that is used to study and visualize human physiology by the detection of positron-emitting radiopharmaceuticals. Information about metabolism, receptor/enzyme function, and biochemical mechanisms in living tissue can be obtained directly from PET experiments. In particular, the interest in 18F-labeled proteins remains high for both diagnoses and therapy monitoring purposes. The development of labeling strategies for the synthesis of new 18F labeled protein is, however, not trivial. 18F-containing prosthetic groups are often required for protein labeling to obtain high yield under mild labeling conditions and keep the bioactive character of the proteins. This review highlights key aspects of protein 18F-labeling method and discussed representative examples including 18F-labeled human serum albumin, 18F-labeled Annexin V, 18F-labeled HER2 affibody, and 18F-labeled low density lipoprotein.
Keywords: 18F, Amine reactive prosthetic groups, Carboxylic acid reactive prosthetic groups, Thiol-reactive prosthetic groups, 18F-Labeled proteins, Positron emission tomography (PET)
Current Pharmaceutical Biotechnology
Title: 18F-Labeled Proteins
Volume: 11 Issue: 6
Author(s): Zhanhong Wu and Fouad Kandeel
Affiliation:
Keywords: 18F, Amine reactive prosthetic groups, Carboxylic acid reactive prosthetic groups, Thiol-reactive prosthetic groups, 18F-Labeled proteins, Positron emission tomography (PET)
Abstract: Positron emission tomography (PET) is a powerful and rapidly developing area of molecular imaging that is used to study and visualize human physiology by the detection of positron-emitting radiopharmaceuticals. Information about metabolism, receptor/enzyme function, and biochemical mechanisms in living tissue can be obtained directly from PET experiments. In particular, the interest in 18F-labeled proteins remains high for both diagnoses and therapy monitoring purposes. The development of labeling strategies for the synthesis of new 18F labeled protein is, however, not trivial. 18F-containing prosthetic groups are often required for protein labeling to obtain high yield under mild labeling conditions and keep the bioactive character of the proteins. This review highlights key aspects of protein 18F-labeling method and discussed representative examples including 18F-labeled human serum albumin, 18F-labeled Annexin V, 18F-labeled HER2 affibody, and 18F-labeled low density lipoprotein.
Export Options
About this article
Cite this article as:
Wu Zhanhong and Kandeel Fouad, 18F-Labeled Proteins, Current Pharmaceutical Biotechnology 2010; 11 (6) . https://dx.doi.org/10.2174/138920110792246564
DOI https://dx.doi.org/10.2174/138920110792246564 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress on Neutralizing Antibodies against Hepatitis B Virus and its Implications
Infectious Disorders - Drug Targets RhoGEFs in Cell Motility: Novel Links Between Rgnef and Focal Adhesion Kinase
Current Molecular Medicine Role of Radiopharmaceuticals in Development of Inhaled Drugs
Current Pharmaceutical Design Herpes Simplex Viruses in Antiviral Drug Discovery
Current Pharmaceutical Design From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Sequential Bilateral Internal Jugular Vein Thrombosis: A Case Report and Review of this Rare Medical Entity
Vascular Disease Prevention (Discontinued) Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry Origins, Structures, and Bioactivities of Secondary Metabolites from Marine-derived Penicillium Fungi
Mini-Reviews in Medicinal Chemistry MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Interleukin-26, a Highly Cationic T-Cell Cytokine Targeting Epithelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Maternal Serum Biomarkers in the Early Diagnosis of Ectopic Pregnancy
Current Chemical Biology Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets A Review of Chemotherapy and Photodynamic Therapy for Lung Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry ARC - Augmented Renal Clearance
Current Pharmaceutical Biotechnology Pivotal Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Inflammatory Pulmonary Diseases
Current Protein & Peptide Science RNA Splicing: Basic Aspects Underlie Antitumor Targeting
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs in Cancer: Small Molecules, Big Chances
Anti-Cancer Agents in Medicinal Chemistry Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
Current Cancer Drug Targets